United Therapeutics Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 1.41 B

United Therapeutics Corporation Operating Cash Flow is USD 1.41 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 44.11% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • United Therapeutics Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 979.70 M, a 10.25% change year over year.
  • United Therapeutics Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 888.60 M, a 11.48% change year over year.
  • United Therapeutics Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 797.10 M, a 26.34% change year over year.
  • United Therapeutics Corporation Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 630.90 M, a -0.71% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities